<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085175</url>
  </required_header>
  <id_info>
    <org_study_id>LMI 1195-201</org_study_id>
    <nct_id>NCT01085175</nct_id>
  </id_info>
  <brief_title>Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing</brief_title>
  <acronym>LMI1195-201</acronym>
  <official_title>A Multicenter, Phase II, Open Label Trial to Determine Optimal Imaging Parameters and Assess the Safety of LMI 1195 in Low Risk Patients and Heart Failure Patients With a History of Firing of an Implantable Cardioverter-Defibrillator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lantheus Medical Imaging</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine the optimal imaging parameters and assess&#xD;
      the safety of LMI1195 -101 in Heart Failure subjects at Low and High Risk of cardiac events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  To determine the optimal imaging protocol for a single dose of LMI1195 during positron&#xD;
           emission tomography (PET) for the intended study population.&#xD;
&#xD;
        -  To assess the safety and tolerability of LMI1195 in patients at low risk of ventricular&#xD;
           arrhythmia (&quot;low risk patients&quot;) and heart failure patients with a history of firing of&#xD;
           an implantable cardioverter defibrillator (ICD) within 6 months prior to enrollment, a&#xD;
           documented ejection fraction (EF) ≤ 35%, and a prior diagnosis of NYHA Class II-III&#xD;
           heart failure (&quot;heart failure patients&quot;) who are undergoing PET imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor is re-evaluating the clinical development path&#xD;
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose acquisition time product, target and non-target F18 count density</measure>
    <time_frame>Approximately one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Image Quality Data Variability across age &amp; sex stratification Determine Retention Index Values Determine Heart to Mediastinal Ratio Evaluate additional image derived markers that may have predictive value</measure>
    <time_frame>Approximately one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low risk Heart Failure patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMI 1195</intervention_name>
    <description>Single bolus intravenous injection of LMI 1195</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>LMI 1195-101 Clinical Trial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant female ≥ 18 years of age&#xD;
&#xD;
          -  a body weight that is &lt;450 pounds&#xD;
&#xD;
          -  Be able to lie flat for at least 2-hour intervals&#xD;
&#xD;
          -  Have a normal left ventricular ejection fraction (i.e., ≥ 55% for cohort one or ≤35%&#xD;
             for cohort two) by multiple gate acquisition scan (MUGA), echocardiogram or single&#xD;
             photon emission computed tomography (SPECT) within 90 days prior, but no less than 3&#xD;
             days prior to enrollment.&#xD;
&#xD;
          -  Have been scheduled to undergo or have undergone a SPECT or an approved PET perfusion&#xD;
             imaging study performed within 90 days prior to, but no less than 3 days prior to&#xD;
             enrollment. to and within the study timeline must be reviewed and deemed acceptable by&#xD;
             the judgment of the investigator) (Additional More Specific Criteria can be accessed&#xD;
             by contacting an LMI representative)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of diabetes, coronary artery disease, myocardial infarction heart&#xD;
             arrhythmia (except sinus arrhythmia), heart failure, cardiomyopathy (e.g. restrictive,&#xD;
             infiltrative or hypertrophic cardiomyopathy), constrictive pericarditis, myocarditis,&#xD;
             complex congenital disease, surgically correctable valvular disease, and/or&#xD;
             inoperable, obstructive valvular disease, pacemaker, syncope, transient ischemic&#xD;
             attack (TIA) or cerebrovascular accident (CVA), Parkinson's disease, degenerative&#xD;
             cerebral disease, or organ transplantation.significant comorbid conditions&#xD;
&#xD;
          -  Have undergone major surgery within 4 weeks prior to enrollment or planned within 3&#xD;
             weeks after completion of the study.&#xD;
&#xD;
          -  Unexplained syncope within 5 years.&#xD;
&#xD;
          -  A life expectancy of &lt; 1 year, from any cause.&#xD;
&#xD;
          -  Are currently participating in another clinical trial of an investigational product.&#xD;
&#xD;
          -  Have clinically significant laboratory abnormalities (e.g., liver enzymes, creatinine,&#xD;
             etc.).&#xD;
&#xD;
          -  Have a history of smoking within 1 month of enrollment.&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Have a history of major psychiatric disorder, active alcohol/drug abuse, and/or&#xD;
             history of non-compliance.&#xD;
&#xD;
          -  Receipt of any radiopharmaceutical within a period equal to 10 half-lives of the&#xD;
             isotope (e.g., for 99mTc, a period of 60 hours; for 111In, a period of 28 days) prior&#xD;
             to enrollment or receipt of any radiopharmaceutical containing iodine within a period&#xD;
             of 3 months prior to enrollment.&#xD;
&#xD;
          -  Have received any of the following medications within 30 days prior to enrollment,&#xD;
             because of confounding effects to the autonomic nervous system: albuterol (Alupent,&#xD;
             Ventolin within 24 hours), Dobutamine (Dobutrex), Dopamine (Intropin), Epinephrine&#xD;
             (Adrenalin), Isoproterenol, Phenylephrine (Neo-Synephrine), Metaraminol (Aramine),&#xD;
             Norepinephrine (Levophed), furazolidone (Furoxone), tricyclic antidepressants (Adapin,&#xD;
             Asendin, Aventyl, Elavil, Endep, Norpramin, Pamelor, Sinequan, Surmontil, Tofranil,&#xD;
             Vivactil), guanethidine (Ismelin), methyldopa (Aldomet). Over the counter herbs that&#xD;
             have been reported to interact with adrenergic amines are excluded: ephedra (ma&#xD;
             huang), St. John's wort; alfalfa; hibiscus; ginseng; angelica (dong quai); and&#xD;
             yohimbe.&#xD;
&#xD;
          -  Are not suitable subjects for completion of any screening or trial procedures&#xD;
             including PET, scans &amp; laboratory testing,&#xD;
&#xD;
          -  Receipt of any radiopharmaceutical within a period of time that the agent has not&#xD;
             decayed below background levels&#xD;
&#xD;
          -  Have metal that cannot be removed from the body located in the thorax, Receiving Class&#xD;
             I or III antiarrhythmic drug therapy, except for amiodarone.&#xD;
&#xD;
        (Additional More Specific Criteria can be accessed by contacting an LMI representative)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Lee, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lantheus Medical Imaging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure,</keyword>
  <keyword>PET Imaging,</keyword>
  <keyword>Implantable Cardioverter-Defibrillator,</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

